NovoCure (NASDAQ:NVCR) and Ambu A/S (OTCMKTS:AMBBY) Head to Head ContrastDefense World · 6 days ago
Novocure: A Mispriced Cash-Generating Biotech With Upside PotentialSeeking Alpha · Oct 13, 2026
Reviewing NeurAxis (NASDAQ:NRXS) and NovoCure (NASDAQ:NVCR)Defense World · Oct 12, 2026
Critical Survey: Medline (NASDAQ:MDLN) & NovoCure (NASDAQ:NVCR)Defense World · Oct 11, 2026
Novocure's Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic CancerBusiness Wire · Oct 1, 2026
NovoCure Limited $NVCR Stake Trimmed by Corient Private Wealth LPDefense World · Sep 28, 2026NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 23, 2026 | -$0.33 | -$0.13 | Beat |
| Apr 30, 2026 | -$0.51 | -$0.62 | Miss |
| Feb 26, 2026 | -$0.41 | -$0.22 | Beat |
| Oct 30, 2025 | -$0.42 | -$0.33 | Beat |
| Jul 24, 2025 | -$0.39 | -$0.36 | Beat |
| Apr 24, 2025 | -$0.47 | -$0.31 | Beat |